Standard BioTools Swaps Mass Cytometry Buyer: Element Biosystems Replaces Multiplex Bio in $5.5M Deal
LAB sits 20% above its 52-week low of $0.625.
Summary
Standard BioTools replaced its Mass Cytometry buyer with Element Biosystems in a $5.5 million cash deal that improves net cash by ~$15 million versus the prior Multiplex Bio agreement.
Key Events · M&A and Partnerships · LAB
-
New Buyer for Mass Cytometry Business
The Multiplex Bio purchase agreement has been terminated, and a new Share and Asset Purchase Agreement with Element Biosystems, LLC, a GMT Venture subsidiary, is now in place for $5.5 million in cash.
-
Net Cash Improvement of ~$15M
The Element deal eliminates a $10 million working capital loan obligation required under the Multiplex Bio agreement, increasing net cash position by approximately $15 million after termination and transaction fees.
-
Termination Fee Paid to Multiplex Bio
A $1.5 million termination fee was paid to Multiplex Bio, with GMT Venture contributing $1.0 million on the Company's behalf.
-
Closing Conditions and Timeline
The Element transaction is expected to close by end of 2026, substantially concurrently with the Treeline merger, subject to stockholder approval and other customary conditions.
Analysis · LAB · Life Sciences
The July 28 agreement with Multiplex Bio has been terminated, and a new deal with Element Biosystems, a GMT Venture subsidiary, is now in place for $5.5 million in cash. While the headline number is smaller than the prior up-to-$10 million seller's note, the new structure eliminates a $10 million working capital loan obligation, improving net cash by approximately $15 million after fees. That cash directly feeds the exchange ratio calculation for the pending Treeline reverse merger, so this is not just a divestiture update — it strengthens the balance sheet going into the merger vote. The deal remains subject to stockholder approval and Treeline merger closing, expected by end of 2026.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.7M. The 52-week trading range was $0.63 to $1.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.